Why the study?
HER-2-positive breast cancer targeted drugs exhibit varying degrees of cardiotoxicity in clinical applications, but the mechanism of their cardiotoxicity remains unclear.
What are the clinical manifestations and epidemiological characteristics of cardiotoxicity associated with HER-2 targeted therapeutic drugs in patients with HER-2-positive breast cancer?
What are the clinical manifestations and epidemiological characteristics of cardiotoxicity associated with HER-2 targeted therapeutic drugs in patients with HER-2-positive breast cancer?
This review categorizes HER-2 targeted therapies based on their cardiotoxic profiles, emphasizing the need for cardiac monitoring (especially for LVEF decline and heart failure) during breast cancer treatment.
Breast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive. Targeted therapeutic agents, represented by trastuzumab, have been effective in improving the survival rate of HER-2-positive breast cancer patients. However, in clinical applications, this type of targeted drugs exhibits varying degrees of cardiotoxicity, and the mechanism of their cardiotoxicity is currently unclear. In this paper, we classify them into three categories: monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate (ADCs). We list the evidence of cardiotoxicity for various drugs based on current clinical trials and summarize their corresponding epidemiological profiles. We also discuss the regulation of cardiotoxicity from three perspectives: clinical biomarkers of cardiotoxicity, permissive cardiotoxicity, and the current status of cardiotoxicity regulation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: